HC Wainwright Has Positive Forecast for ARWR Q2 Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – HC Wainwright lifted their Q2 2026 EPS estimates for shares of Arrowhead Pharmaceuticals in a report issued on Wednesday, January 21st. HC Wainwright analyst P. Trucchio now expects that the biotechnology company will post earnings of ($0.97) per share for the quarter, up from their prior estimate of ($1.05). HC Wainwright currently has a “Buy” rating and a $100.00 target price on the stock. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Arrowhead Pharmaceuticals’ Q3 2026 earnings at ($1.26) EPS, FY2026 earnings at ($2.03) EPS, Q1 2027 earnings at ($0.99) EPS, Q2 2027 earnings at ($1.23) EPS, Q3 2027 earnings at ($1.28) EPS, Q4 2027 earnings at ($0.02) EPS and FY2027 earnings at ($3.51) EPS.

A number of other research analysts also recently weighed in on ARWR. Bank of America upped their target price on Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Royal Bank Of Canada upped their price target on Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the stock an “outperform” rating in a research note on Thursday, December 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a report on Wednesday. Piper Sandler restated an “overweight” rating and set a $110.00 target price (up previously from $100.00) on shares of Arrowhead Pharmaceuticals in a report on Tuesday, January 13th. Finally, B. Riley upped their target price on shares of Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the stock a “buy” rating in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $81.67.

Arrowhead Pharmaceuticals Price Performance

ARWR stock opened at $67.05 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 4.86 and a quick ratio of 4.86. Arrowhead Pharmaceuticals has a 1 year low of $9.57 and a 1 year high of $76.76. The firm has a 50-day moving average of $62.41 and a 200 day moving average of $39.95. The company has a market cap of $9.11 billion, a P/E ratio of -838.02 and a beta of 1.21.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Farther Finance Advisors LLC grew its holdings in shares of Arrowhead Pharmaceuticals by 2,923.0% during the fourth quarter. Farther Finance Advisors LLC now owns 11,941 shares of the biotechnology company’s stock valued at $793,000 after buying an additional 11,546 shares during the last quarter. Financial Enhancement Group LLC bought a new position in Arrowhead Pharmaceuticals in the 4th quarter valued at approximately $373,000. State of Alaska Department of Revenue boosted its stake in Arrowhead Pharmaceuticals by 1.2% during the 4th quarter. State of Alaska Department of Revenue now owns 70,399 shares of the biotechnology company’s stock valued at $4,673,000 after purchasing an additional 831 shares during the last quarter. Choreo LLC purchased a new stake in Arrowhead Pharmaceuticals during the 4th quarter valued at $450,000. Finally, Ritholtz Wealth Management bought a new stake in shares of Arrowhead Pharmaceuticals in the 4th quarter worth $262,000. Institutional investors own 62.61% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Christopher Richard Anzalone sold 13,187 shares of the company’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $66.10, for a total value of $871,660.70. Following the transaction, the chief executive officer owned 3,792,739 shares in the company, valued at $250,700,047.90. The trade was a 0.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider James C. Hamilton sold 40,164 shares of the stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $63.11, for a total transaction of $2,534,750.04. Following the sale, the insider directly owned 171,958 shares in the company, valued at $10,852,269.38. This trade represents a 18.93% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 510,836 shares of company stock valued at $33,603,060. Company insiders own 4.30% of the company’s stock.

More Arrowhead Pharmaceuticals News

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised several near‑term and FY2026/FY2027 EPS estimates, reiterated a “Buy” rating and a $100 price target — the firm says improving forecasts and program progress support upside. HC Wainwright Forecasts Strong Price Appreciation for Arrowhead Pharmaceuticals
• Positive Sentiment: B. Riley bumped its price target to $101 (from $61) and kept a “Buy” stance, implying significant upside from recent levels and signaling continued analyst conviction after Arrowhead’s program updates. B. Riley Raises ARWR Price Target to $101
• Positive Sentiment: Piper Sandler highlighted Arrowhead’s pipeline ahead of Phase III hypertriglyceridemia data and has increased its target (reported lift to $110), underscoring the potential for a clinical readout to re‑rate the stock if data are positive. Piper Sandler Highlights Arrowhead Pipeline
• Neutral Sentiment: Broader coverage pieces (InsiderMonkey/TheFly) recap the analyst upgrades and pipeline milestones — useful for context but largely reiterative of the broker notes above. InsiderMonkey: Piper Sandler Highlights Arrowhead
• Negative Sentiment: Despite the upgrades, shares are down today amid lower‑than‑average volume — likely profit‑taking following the recent run and continued investor caution given persistent GAAP losses and upcoming binary clinical readouts (which carry upside but also clinical risk).

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.